{
  "meta": {
    "title": "Approach_To_Anemia_-_Part_1",
    "url": "https://brainandscalpel.vercel.app/approach-to-anemia-part-1-53734452.html",
    "scrapedAt": "2025-11-29T18:24:50.179Z"
  },
  "questions": [
    {
      "id": 20594,
      "choices": [
        {
          "id": 82339,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2.5% </span></span></span></p>"
        },
        {
          "id": 82340,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3.0% </span></span></span></p>"
        },
        {
          "id": 82341,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5.0% </span></span></span></p>"
        },
        {
          "id": 82342,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10.0%</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old female presents with fatigue and pallor. Her reticulocyte count is 5%, hemoglobin is 9 g/dL, and hematocrit is 28%. What is her corrected reticulocyte count?</span></span></span></p>",
      "unique_key": "Q3969235",
      "question_audio": null,
      "question_video": null,
      "map_id": 20608,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 3.0%.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The corrected reticulocyte count is calculated by multiplying the reticulocyte count by the ratio of the patient&#39;s hemoglobin to a normal hemoglobin (15 g/dL for males, 14 g/dL for females). In this case, the corrected reticulocyte count is 5% * (9/14) = 3.2%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The corrected reticulocyte count adjusts for the degree of anemia, providing a more accurate reflection of bone marrow activity.</span></span></span></p>",
      "correct_choice_id": 82340,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20595,
      "choices": [
        {
          "id": 82343,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemoglobin electrophoresis </span></span></span></p>"
        },
        {
          "id": 82344,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum B12 and folate levels </span></span></span></p>"
        },
        {
          "id": 82345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Direct antiglobulin test (DAT) </span></span></span></p>"
        },
        {
          "id": 82346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bone marrow biopsy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of heavy alcohol use presents with macrocytic anemia on a routine blood test. His MCV is 105 fL and his RPI is 3.5. What is the next best step in her management?</span></span></p>",
      "unique_key": "Q9240069",
      "question_audio": null,
      "question_video": null,
      "map_id": 20609,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Serum B12 and folate levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is the most direct and cost-effective way to assess for deficiencies in these vitamins, which are common causes of macrocytic anemia, especially in patients with a history of alcohol abuse</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hemoglobin electrophoresis:</span></strong><span style=\"font-size:12.0pt\"> This test is used to identify abnormal types of hemoglobin, as seen in conditions like sickle cell disease or thalassemia. It is not helpful in diagnosing vitamin B12 or folate deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong> <strong><span style=\"font-size:12.0pt\">Direct antiglobulin test (DAT):</span></strong><span style=\"font-size:12.0pt\"> This test is used to diagnose autoimmune hemolytic anemias, where the body&#39;s immune system attacks its own red blood cells. This is not the primary concern in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bone</span></strong> <strong><span style=\"font-size:12.0pt\">marrow biopsy</span></strong><span style=\"font-size:12.0pt\">: While a bone marrow biopsy can reveal megaloblastic changes (characteristic of B12/folate deficiency), it is an invasive procedure and usually reserved for cases where the diagnosis is unclear or there is suspicion of other marrow disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with macrocytic anemia and a history suggestive of vitamin B12 or folate deficiency, the most helpful initial test is measuring serum B12 and folate levels.</span></span></span></p>",
      "correct_choice_id": 82344,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20598,
      "choices": [
        {
          "id": 82355,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folate deficiency </span></span></span></p>"
        },
        {
          "id": 82356,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82357,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemolytic anemia </span></span></span></p>"
        },
        {
          "id": 82358,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic kidney disease presents with fatigue and shortness of breath. His laboratory findings show a MCV 88 fL with a low reticulocyte production index (RPI &lt; 2). Which of the following is the MOST likely cause of his anemia?</span></span></p>",
      "unique_key": "Q6200976",
      "question_audio": null,
      "question_video": null,
      "map_id": 20612,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anemia of chronic disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic kidney disease is a classic cause of anemia of chronic disease, characterized by normocytic anemia with low RPI due to impaired erythropoietin production and iron utilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Folate deficiency:</span></strong><span style=\"font-size:12.0pt\"> Macrocytic anemia with high RPI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron deficiency anemia:</span></strong><span style=\"font-size:12.0pt\"> Microcytic anemia with low RPI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hemolytic anemia:</span></strong><span style=\"font-size:12.0pt\"> Normocytic/macrocytic anemia with high RPI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normocytic anemia with low RPI in the setting of chronic disease should prompt consideration of anemia of chronic disease.</span></span></span></p>",
      "correct_choice_id": 82358,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20600,
      "choices": [
        {
          "id": 82363,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease (ACD) </span></span></span></p>"
        },
        {
          "id": 82364,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Iron deficiency anemia (IDA) </span></span></span></p>"
        },
        {
          "id": 82365,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Thalassemia trait </span></span></span></p>"
        },
        {
          "id": 82366,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Sideroblastic anemia (SA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of rheumatoid arthritis presents with fatigue and a normocytic anemia (MCV 90 fL). His iron studies show the following:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum iron: 30 mcg/dL (normal: 60-170 mcg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TIBC: 200 mcg/dL (normal: 240-450 mcg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ferritin: 350 ng/mL (normal: 20-500 ng/mL)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q7331894",
      "question_audio": null,
      "question_video": null,
      "map_id": 20614,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Anemia of chronic disease (ACD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Anemia of chronic disease (ACD):</span></strong><span style=\"font-size:12.0pt\"> This patient&#39;s presentation and lab values are consistent with ACD. The inflammatory response in rheumatoid arthritis disrupts iron metabolism, leading to low serum iron and TIBC, despite adequate iron stores (as indicated by the normal to elevated ferritin).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron deficiency anemia (IDA):</span></strong><span style=\"font-size:12.0pt\"> IDA would typically present with low serum iron, high TIBC, and low ferritin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thalassemia trait:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic condition causing microcytic anemia, not normocytic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sideroblastic anemia (SA):</span></strong><span style=\"font-size:12.0pt\"> SA is less likely in this scenario as it often presents with elevated serum iron and ferritin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the distinct pattern of iron studies in anemia of chronic disease (low serum iron, low TIBC, and normal to elevated ferritin) is crucial for differentiating it from iron deficiency anemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the setting of a chronic inflammatory condition like rheumatoid arthritis, anemia of chronic disease is a common consideration.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 82363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20605,
      "choices": [
        {
          "id": 82383,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia (IDA) </span></span></span></p>"
        },
        {
          "id": 82384,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Sideroblastic anemia (SA) </span></span></span></p>"
        },
        {
          "id": 82385,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Thalassemia trait </span></span></span></p>"
        },
        {
          "id": 82386,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease (ACD)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic alcoholism presents with fatigue, pallor, and a microcytic anemia. His iron studies reveal elevated iron, TIBC, and ferritin. Blood smear shows basophilic stippling. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q3468913",
      "question_audio": null,
      "question_video": null,
      "map_id": 20616,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Sideroblastic anemia (SA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The elevated iron indices, presence of basophilic stippling, and history of alcohol abuse are consistent with sideroblastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency anemia (IDA):&nbsp;</span></strong><span style=\"font-size:12.0pt\">IDA would typically present with microcytic anemia but with <em>low</em> serum iron, <em>high</em> TIBC, and <em>low</em> ferritin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thalassemia trait:</span></strong><span style=\"font-size:12.0pt\"> While thalassemia can also cause microcytic anemia, it would not typically cause elevated iron indices and basophilic stippling. Hemoglobin electrophoresis would be needed for definitive diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Anemia of chronic disease (ACD):</span></strong><span style=\"font-size:12.0pt\"> ACD usually presents as a normocytic anemia, though it can occasionally be microcytic. However, the iron indices in ACD would show low serum iron, low TIBC, and normal or elevated ferritin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">the classic presentation and laboratory findings of sideroblastic anemia, particularly in the setting of chronic alcoholism:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microcytic anemia: Small red blood cells (MCV &lt; 80 fL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated iron indices: High serum iron, high total iron binding capacity (TIBC), and high ferritin</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basophilic stippling: Characteristic finding on peripheral blood smear</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">History of alcohol abuse: A risk factor for sideroblastic anemia.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 82384,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20613,
      "choices": [
        {
          "id": 82415,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalassemia </span></span></span></p>"
        },
        {
          "id": 82416,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sideroblastic anemia </span></span></span></p>"
        },
        {
          "id": 82417,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease </span></span></span></p>"
        },
        {
          "id": 82418,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with microcytic anemia fails to respond to oral iron supplementation. Which of the following should be considered in the differential diagnosis?</span></span></p>",
      "unique_key": "Q9134627",
      "question_audio": null,
      "question_video": null,
      "map_id": 20619,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) All of the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the mentioned conditions can present with microcytic anemia and may not respond to oral iron supplementation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microcytic anemia with failed iron therapy suggests causes beyond iron deficiency. Consider thalassemia, sideroblastic anemia, or anemia of chronic disease.</span></span></span></p>",
      "correct_choice_id": 82418,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20620,
      "choices": [
        {
          "id": 82443,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal serum iron, normal TIBC, and normal ferritin </span></span></span></p>"
        },
        {
          "id": 82444,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum iron, high TIBC, and low ferritin </span></span></span></p>"
        },
        {
          "id": 82445,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum iron, low TIBC, and high ferritin </span></span></span></p>"
        },
        {
          "id": 82446,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High serum iron, normal TIBC, and high ferritin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with heavy menstrual bleeding presents with fatigue and pallor. Her lab results show a microcytic anemia with an elevated red cell distribution width and a low reticulocyte count. Which of the following laboratory findings would MOST likely be seen in this patient?</span></span></p>",
      "unique_key": "Q3229315",
      "question_audio": null,
      "question_video": null,
      "map_id": 20620,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Low serum iron, high TIBC, and low ferritin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory findings are consistent with iron deficiency anemia (IDA). In IDA, iron stores are depleted, leading to low serum iron and ferritin levels. The body attempts to compensate by increasing iron binding capacity (TIBC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of microcytic anemia, elevated RDW, and low reticulocyte count with low serum iron, high TIBC, and low ferritin strongly suggests iron deficiency anemia.</span></span></span></p>",
      "correct_choice_id": 82444,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20626,
      "choices": [
        {
          "id": 82467,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82468,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease </span></span></span></p>"
        },
        {
          "id": 82469,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-thalassemia trait </span></span></span></p>"
        },
        {
          "id": 82470,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha-thalassemia trait</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman of Mediterranean descent is found to have mild microcytic anemia on routine blood work. Her iron studies are normal, and hemoglobin electrophoresis reveals an elevated HbA2 level. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q1226679",
      "question_audio": null,
      "question_video": null,
      "map_id": 20621,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. C) Beta-thalassemia trait</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microcytic anemia with normal iron studies and elevated HbA2 on electrophoresis are characteristic of beta-thalassemia trait.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency anemia (IDA):</span></strong><span style=\"font-size:12.0pt\"> While IDA is the most common cause of microcytic anemia, it would typically present with abnormal iron studies (low serum iron, low ferritin, and high total iron-binding capacity).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anemia of chronic disease (ACD):</span></strong><span style=\"font-size:12.0pt\"> ACD is typically normocytic, but can occasionally be microcytic. However, it would not typically cause elevated HbA2 levels on electrophoresis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Alpha-thalassemia trait:</span></strong><span style=\"font-size:12.0pt\"> Alpha thalassemia is another inherited disorder that can cause microcytic anemia, but it would not typically cause elevated HbA2 levels. Instead, it may be associated with an elevated HbH level or a normal hemoglobin electrophoresis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-thalassemia is a common cause of microcytic anemia in individuals of Mediterranean descent. Hemoglobin electrophoresis is essential for diagnosis.</span></span></span></p>",
      "correct_choice_id": 82469,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20635,
      "choices": [
        {
          "id": 82503,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency </span></span></span></p>"
        },
        {
          "id": 82504,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folate deficiency </span></span></span></p>"
        },
        {
          "id": 82505,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immune-mediated hemolysis </span></span></span></p>"
        },
        {
          "id": 82506,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired erythropoiesis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old female with a history of systemic lupus erythematosus (SLE) presents with fatigue, pallor, and jaundice. Her laboratory evaluation reveals a normocytic anemia with a positive direct antiglobulin test (DAT). Which of the following is the most likely mechanism of her anemia?</span></span></p>",
      "unique_key": "Q5875613",
      "question_audio": null,
      "question_video": null,
      "map_id": 20624,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Immune-mediated hemolysis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SLE is associated with autoimmune hemolytic anemia, which is characterized by normocytic anemia, positive DAT (indicating the presence of antibodies against red blood cells), and often jaundice due to increased bilirubin from red blood cell breakdown.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency:</span></strong><span style=\"font-size:12.0pt\"> While iron deficiency can cause anemia, it typically results in a microcytic anemia (smaller red blood cells), not normocytic. Additionally, it would not explain the positive DAT or jaundice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Folate deficiency:</span></strong><span style=\"font-size:12.0pt\"> Folate deficiency can lead to megaloblastic anemia, which is a type of macrocytic anemia (larger red blood cells), not normocytic. It would also not explain the positive DAT or jaundice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Impaired erythropoiesis:</span></strong><span style=\"font-size:12.0pt\"> While SLE can sometimes affect the bone marrow and lead to impaired red blood cell production, it&#39;s less common than immune-mediated hemolysis and wouldn&#39;t explain the positive DAT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of normocytic anemia, positive DAT, and jaundice in a patient with SLE strongly points toward immune-mediated hemolysis as the underlying cause.</span></span></span></p>",
      "correct_choice_id": 82505,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20636,
      "choices": [
        {
          "id": 82507,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">0.5 mg </span></span></span></p>"
        },
        {
          "id": 82508,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 mg </span></span></span></p>"
        },
        {
          "id": 82509,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1.4 mg </span></span></span></p>"
        },
        {
          "id": 82510,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2 mg</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a healthy adult male, the average daily iron absorption from dietary sources is approximately:</span></span></p>",
      "unique_key": "Q8342379",
      "question_audio": null,
      "question_video": null,
      "map_id": 20625,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 1 mg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult men typically require about ~1 mg of iron to be absorbed from the diet daily to maintain iron balance and replace losses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron Absorption of ~1mg/d is required from the diet in men, and 1.4mg/d in women to maintain homeostasis.</span></span></span></p>",
      "correct_choice_id": 82508,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20638,
      "choices": [
        {
          "id": 82515,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Negative iron balance </span></span></span></p>"
        },
        {
          "id": 82516,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron-deficient erythropoiesis </span></span></span></p>"
        },
        {
          "id": 82517,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82518,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron overload</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman with heavy menstrual periods complains of fatigue and brittle nails. Her lab results show a serum ferritin of 18 ng/mL and her TIBC was 370. Peripheral smear turns out to be normal. What is the MOST likely stage of iron deficiency in this patient?</span></span></p>",
      "unique_key": "Q6291933",
      "question_audio": null,
      "question_video": null,
      "map_id": 20627,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Negative iron balance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Negative iron balance:</span></strong><span style=\"font-size:12.0pt\"> This is the earliest stage of iron deficiency. Iron stores are depleted, leading to low serum ferritin. However, at this stage, hemoglobin and hematocrit might still be within the normal range as the body has not yet reached the point of insufficient iron for red blood cell production. The elevated TIBC supports this diagnosis, reflecting the body&#39;s increased capacity to bind iron due to low stores. The normal peripheral smear indicates that red blood cell morphology has not yet been affected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron-deficient erythropoiesis:</span></strong><span style=\"font-size:12.0pt\"> In this stage, hemoglobin and hematocrit would likely start to decline.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Iron deficiency anemia:</span></strong><span style=\"font-size:12.0pt\"> This stage is characterized by a clear drop in hemoglobin and hematocrit, along with microcytic and hypochromic red blood cells on peripheral smear.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Iron overload:</span></strong><span style=\"font-size:12.0pt\"> This is the opposite of iron deficiency and is associated with elevated ferritin, normal to low TIBC, and other systemic complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early detection of iron deficiency through low serum ferritin is crucial for timely intervention and prevention of progression to iron deficiency anemia.</span></span></span></p>",
      "correct_choice_id": 82515,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20640,
      "choices": [
        {
          "id": 82523,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ascorbic acid </span></span></span></p>"
        },
        {
          "id": 82524,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Orange juice </span></span></span></p>"
        },
        {
          "id": 82525,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Meat </span></span></span></p>"
        },
        {
          "id": 82526,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antacids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following substances can IMPAIR the absorption of iron supplements?</span></span></span></p>",
      "unique_key": "Q9183200",
      "question_audio": null,
      "question_video": null,
      "map_id": 20629,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Antacids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antacids neutralize stomach acid, which is necessary for the conversion of ferric iron (Fe3+) to ferrous iron (Fe2+), the form that is more readily absorbed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option (A, B, C):</span></strong><span style=\"font-size:12.0pt\"> Vitamin C (in <strong>ascorbic acid</strong> and <strong>orange juice)</strong> and <strong>meat</strong> can all improve iron absorption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients taking iron supplements should avoid taking antacids concurrently, as this can reduce absorption.</span></span></span></p>",
      "correct_choice_id": 82526,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20642,
      "choices": [
        {
          "id": 82531,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a common and effective oral iron supplement. </span></span></span></p>"
        },
        {
          "id": 82532,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It should be taken on an empty stomach for optimal absorption. </span></span></span></p>"
        },
        {
          "id": 82533,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is often combined with ascorbic acid to enhance absorption. </span></span></span></p>"
        },
        {
          "id": 82534,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is the iron preparation with the highest elemental iron content.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old woman with iron deficiency anemia is prescribed ferrous sulfate. Which of the following statements about ferrous sulphate is INCORRECT?</span></span></span></p>",
      "unique_key": "Q2508942",
      "question_audio": null,
      "question_video": null,
      "map_id": 20631,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) It is the iron preparation with the highest elemental iron content</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While ferrous sulfate( Iron content &ndash; 65mg) is a common and effective iron supplement, it does not have the highest elemental iron content. Ferrous fumarate( iron content - 107) has a slightly higher elemental iron content.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is a common and effective oral iron supplement:</span></strong><span style=\"font-size:12.0pt\"> This is correct. Ferrous sulfate is widely used and effective for treating iron deficiency anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. It should be taken on an empty stomach for optimal absorption:</span></strong><span style=\"font-size:12.0pt\"> This is also correct. Iron is best absorbed in an acidic environment, so taking it on an empty stomach or with vitamin C (which enhances acidity) improves absorption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It is often combined with ascorbic acid to enhance absorption:</span></strong><span style=\"font-size:12.0pt\"> This is true. Ascorbic acid (vitamin C) helps convert ferric iron to ferrous iron, the form more readily absorbed by the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Different iron preparations vary in their elemental iron content, but most are well absorbed and effective in treating iron deficiency anemia.</span></span></span></p>",
      "correct_choice_id": 82534,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20644,
      "choices": [
        {
          "id": 82539,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They can safely receive any other parenteral iron formulation. </span></span></span></p>"
        },
        {
          "id": 82540,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral iron therapy is the only safe option for them. </span></span></span></p>"
        },
        {
          "id": 82541,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They should be referred for blood transfusion as needed. </span></span></span></p>"
        },
        {
          "id": 82542,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">They may be able to receive alternative parenteral iron formulations under close supervision.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient has experienced anaphylaxis to iron dextran in the past. Which of the following statements is MOST accurate regarding their future management of iron deficiency anemia?</span></span></span></p>",
      "unique_key": "Q1220740",
      "question_audio": null,
      "question_video": null,
      "map_id": 20633,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) They may be able to receive alternative parenteral iron formulations under close supervision.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While a history of anaphylaxis to iron dextran is a serious concern, other parenteral iron preparations with different chemical structures may be tolerated. However, these should be administered with caution, in a setting where anaphylaxis can be managed promptly.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with sensitivity to one iron preparation have been safely treated with other parenteral iron preparations.</span></span></span></p>",
      "correct_choice_id": 82542,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20648,
      "choices": [
        {
          "id": 82555,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ferric gluconate </span></span></span></p>"
        },
        {
          "id": 82556,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron sucrose </span></span></span></p>"
        },
        {
          "id": 82557,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ferric carboxymaltose </span></span></span></p>"
        },
        {
          "id": 82558,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ferric derisomaltose</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with severe iron deficiency anemia requires rapid replenishment of her iron stores. Which of the following parenteral iron preparations would provide the highest amount of iron in a single infusion?</span></span></p>",
      "unique_key": "Q9559193",
      "question_audio": null,
      "question_video": null,
      "map_id": 20637,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Ferric derisomaltose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ferric derisomaltose (Monoferric) can deliver up to 1000 mg of elemental iron in a single infusion, making it the parenteral iron preparation with the highest single-dose capacity. This makes it an attractive option for patients with severe iron deficiency who require rapid iron replenishment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ferric gluconate:</span></strong><span style=\"font-size:12.0pt\"> Delivers a much lower dose of iron per infusion (125 mg).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron sucrose:</span></strong><span style=\"font-size:12.0pt\"> Delivers a lower dose of iron per infusion (200 mg).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ferric carboxymaltose:</span></strong><span style=\"font-size:12.0pt\"> Delivers a lower dose of iron per infusion (750 mg).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ferric derisomaltose is a valuable option for patients with severe iron deficiency anemia who require rapid correction of iron stores, as it allows for the administration of a large dose of iron in a single infusion. However, it&#39;s important to consider potential side effects and contraindications before choosing this preparation.</span></span></span></p>",
      "correct_choice_id": 82558,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20654,
      "choices": [
        {
          "id": 82579,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Within 24-48 hours of starting therapy </span></span></span></p>"
        },
        {
          "id": 82580,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3-4 days after starting therapy </span></span></span></p>"
        },
        {
          "id": 82581,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">7-10 days after starting therapy </span></span></span></p>"
        },
        {
          "id": 82582,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">14-21 days after starting therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with iron deficiency anemia is started on oral iron supplementation. When would you expect to see the PEAK reticulocyte response, indicating that the bone marrow is actively producing new red blood cells?</span></span></p>",
      "unique_key": "Q3811305",
      "question_audio": null,
      "question_video": null,
      "map_id": 20639,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 7-10 days after starting therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The peak reticulocyte response typically occurs within 1-1.5 weeks (7-10 days) after starting iron therapy. This indicates a robust response from the bone marrow to correct the anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong> <strong><span style=\"font-size:12.0pt\">Within 24-48 hours of starting therapy:</span></strong><span style=\"font-size:12.0pt\"> This is too soon to expect a peak response. It takes several days for the bone marrow to ramp up red blood cell production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 3-4 days after starting therapy:</span></strong><span style=\"font-size:12.0pt\"> While the reticulocyte count may start to rise within 3-4 days, the peak response is typically later.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 14-21 days after starting therapy:</span></strong><span style=\"font-size:12.0pt\"> This is too late for the peak response. If there&#39;s no significant increase by this time, it could suggest a lack of response to therapy or an alternative diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The reticulocyte count is a valuable tool for monitoring the response to iron therapy in iron deficiency anemia. An increase in reticulocytes within 4-7 days and a peak response at 7-10 days are expected findings, indicating that the treatment is effective.</span></span></span></p>",
      "correct_choice_id": 82581,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20658,
      "choices": [
        {
          "id": 82595,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal iron absorption </span></span></span></p>"
        },
        {
          "id": 82596,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron malabsorption </span></span></span></p>"
        },
        {
          "id": 82597,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron overload </span></span></span></p>"
        },
        {
          "id": 82598,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman with microcytic anemia is given an iron tolerance test. Two hours after ingesting two iron tablets on an empty stomach, her serum iron level increases by 80 mcg/dL. What is the most likely interpretation of this result?</span></span></p>",
      "unique_key": "Q8823602",
      "question_audio": null,
      "question_video": null,
      "map_id": 20641,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Iron malabsorption</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A normal iron tolerance test should result in an increase in serum iron of at least 100 mcg/dL. An increase of only 80 mcg/dL suggests impaired iron absorption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The iron tolerance test assesses the body&#39;s ability to absorb iron, and a rise of less than 100 mcg/dL suggests malabsorption.</span></span></span></p>",
      "correct_choice_id": 82596,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20673,
      "choices": [
        {
          "id": 82655,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10% </span></span></span></p>"
        },
        {
          "id": 82656,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">20% </span></span></span></p>"
        },
        {
          "id": 82657,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30% </span></span></span></p>"
        },
        {
          "id": 82658,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">40%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In infants who survive Hb Bart&#39;s hydrops fetalis, the approximate percentage that experiences neurodevelopmental delay is:</span></span></span></p>",
      "unique_key": "Q7245822",
      "question_audio": null,
      "question_video": null,
      "map_id": 20645,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 20%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The text states that &quot;neurodevelopmental delay is present in 20% of survivors.&quot; This is a direct reference to the prevalence of neurodevelopmental delay in this specific population.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 10%:</span></strong><span style=\"font-size:12.0pt\"> This underestimates the risk of neurodevelopmental delay in this population.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 30%:</span></strong><span style=\"font-size:12.0pt\"> This overestimates the risk of neurodevelopmental delay in this population.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 40%:</span></strong><span style=\"font-size:12.0pt\"> This is the percentage of survivors who experience growth retardation, not neurodevelopmental delay.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hb Bart&rsquo;s hydrops fetalis is best prevented by screening couples at risk and antenatal diagnosis. Intrauterine therapy and perinatal intensive care have permitted survival of some infants with Hb Bart hydrops fetalis. As growth retardation affects ~40% and neurodevelopmental delay is present in 20% of survivors, prevention is the best approach. </span></span></span></p>",
      "correct_choice_id": 82656,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20686,
      "choices": [
        {
          "id": 82707,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&alpha;&alpha;/&alpha;&alpha; </span></span></span></p>"
        },
        {
          "id": 82708,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">-&alpha;/&alpha;&alpha; </span></span></span></p>"
        },
        {
          "id": 82709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">--/&alpha;&alpha; </span></span></span></p>"
        },
        {
          "id": 82710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">--/-&alpha;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following alpha-globin gene arrangements is MOST likely to be associated with Hemoglobin H (HbH) disease?</span></span></span></p>",
      "unique_key": "Q7990462",
      "question_audio": null,
      "question_video": null,
      "map_id": 20648,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) --/-&alpha;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbH disease is caused by the deletion or inactivation of three out of four alpha-globin genes. The genotype &quot;--/-&alpha;&quot; represents this condition, where one chromosome has both alpha-globin genes deleted, and the other chromosome has one alpha-globin gene deleted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. &alpha;&alpha;/&alpha;&alpha;:&nbsp;</span></strong><span style=\"font-size:12.0pt\">&alpha;-thal.</span><strong> </strong><span style=\"font-size:12.0pt\">With Myelodysplasia - </span><span style=\"font-size:12.0pt\">Mutations in <em>ATRX</em>; striking male predominance. Hematologic findings of HbH disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong> <strong><span style=\"font-size:12.0pt\">-&alpha;/&alpha;&alpha;:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Represents the silent carrier state of alpha-thalassemia, with only one alpha-globin gene deleted. It typically doesn&#39;t cause significant clinical symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong> <strong><span style=\"font-size:12.0pt\">--/&alpha;&alpha;:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Represents alpha-thalassemia trait, where two alpha-globin genes are deleted. This condition can lead to mild anemia but is not associated with HbH disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The specific arrangement and number of alpha-globin gene deletions determine the severity of alpha-thalassemia. HbH disease, a moderate form of the condition, is caused by the deletion or inactivation of three out of four alpha-globin genes, represented by the genotype --/-&alpha; (other gene arrangement: &alpha;<sup>T</sup>&alpha;/- -, &alpha;<sup>T</sup>&alpha;/&alpha;<sup>T</sup>&alpha;)</span></span></span></p>",
      "correct_choice_id": 82710,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20688,
      "choices": [
        {
          "id": 82715,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prevention of RNA polyadenylation and reduced beta-globin production </span></span></span></p>"
        },
        {
          "id": 82716,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Introduction of a stop codon and premature termination of translation </span></span></span></p>"
        },
        {
          "id": 82717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Creation of an alternative splice site in an intron </span></span></span></p>"
        },
        {
          "id": 82718,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Total absence of beta-globin production</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old man with microcytic anemia is found to have a mutation in the 3&#39; end-processing sequence of the beta-globin gene. Which of the following is the MOST likely consequence of this mutation?</span></span></p>",
      "unique_key": "Q6915774",
      "question_audio": null,
      "question_video": null,
      "map_id": 20649,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Prevention of RNA polyadenylation and reduced beta-globin production</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;3&#39; end-processing sequence mutations affect mRNA stability and lead to reduced but not absent beta-globin production (&beta;+ thalassemia).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the 3&#39; end-processing sequence are a specific type of mutation that can cause &beta;+ thalassemia.</span></span></span></p>",
      "correct_choice_id": 82715,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20689,
      "choices": [
        {
          "id": 82719,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Beta-zero (</span><span style=\"font-size:12.0pt\">&beta;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">0) thalassemia </span></span></span></p>"
        },
        {
          "id": 82720,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Beta-plus (</span><span style=\"font-size:12.0pt\">&beta;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">+) thalassemia </span></span></span></p>"
        },
        {
          "id": 82721,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Delta-beta (</span><span style=\"font-size:12.0pt\">&delta;&beta;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">) thalassemia </span></span></span></p>"
        },
        {
          "id": 82722,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hemoglobin Lepore thalassemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman of Mediterranean descent presents with mild anemia and microcytosis. Her iron studies are normal, and genetic testing reveals a change in the promoter region of the beta-globin gene. Which type of beta-thalassemia is she most likely to have?</span></span></p>",
      "unique_key": "Q5095637",
      "question_audio": null,
      "question_video": null,
      "map_id": 20652,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Beta-plus (&beta;+) thalassemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Single nucleotide changes in the promoter region typically lead to reduced, but not absent, beta-globin production (&beta;+ thalassemia).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Beta-zero (&beta;0) thalassemia:&nbsp;</strong>Caused by severe mutations, not promoter changes, leading to complete absence of beta-globin production. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Delta-beta (&delta;&beta;) thalassemia:&nbsp;</strong>Deletion of both delta and beta globin genes causes a different clinical picture. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hemoglobin Lepore thalassemia</span></strong><span style=\"font-size:12.0pt\">: Rare condition caused by delta-beta globin gene fusion, not promoter mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Promoter mutations are a common cause of milder beta-thalassemia.</span></span></span></p>",
      "correct_choice_id": 82720,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20692,
      "choices": [
        {
          "id": 82731,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82732,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency </span></span></span></p>"
        },
        {
          "id": 82733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sickle cell anemia </span></span></span></p>"
        },
        {
          "id": 82734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-thalassemia intermedia</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a history of mild anemia on routine blood work presents for a follow-up appointment. She reports good energy levels and denies any recent illnesses or blood loss. Her physical examination is unremarkable. A peripheral blood smear is shown in the image. Which of the following hematological conditions is MOST likely represented in this blood smear?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/screenshot-2024-07-31-124914.png\" style=\"height:151px; width:300px\" /></span></span></p>",
      "unique_key": "Q1199028",
      "question_audio": null,
      "question_video": null,
      "map_id": 20654,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. D) Beta-thalassemia intermedia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows target cells and marked variation in cell size (anisocytosis) and shape (poikilocytosis), along with hypochromia (pale red blood cells) and microcytosis (small red blood cells). These are hallmark features of beta-thalassemia intermedia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency anemia:</span></strong><span style=\"font-size:12.0pt\"> While also microcytic and hypochromic, it usually does not exhibit target cells or the degree of poikilocytosis seen here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Vitamin B12 deficiency:</span></strong><span style=\"font-size:12.0pt\"> Causes macrocytic (large red blood cell) anemia, not microcytic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sickle cell anemia:</span></strong><span style=\"font-size:12.0pt\"> Characterized by sickle-shaped red blood cells, which are not present in this image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of target cells, anisocytosis, poikilocytosis, hypochromia and microcytosis in a blood smear strongly suggests beta-thalassemia intermedia.</span></span></span></p>",
      "correct_choice_id": 82734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20693,
      "choices": [
        {
          "id": 82735,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insufficient blood transfusions </span></span></span></p>"
        },
        {
          "id": 82736,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron overload </span></span></span></p>"
        },
        {
          "id": 82737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folate deficiency </span></span></span></p>"
        },
        {
          "id": 82738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-years-old male with a history of beta-thalassemia major has been receiving regular blood transfusions every 3 weeks to maintain a pre-transfusion hemoglobin level of 9.5 g/dL. Despite adherence to his transfusion schedule, he has recently developed fatigue, skin hyperpigmentation and hepatomegaly. Which of the following is the most likely cause of his new symptoms?</span></span></p>",
      "unique_key": "Q5370319",
      "question_audio": null,
      "question_video": null,
      "map_id": 20655,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Iron overload</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regular blood transfusions, while necessary to maintain hemoglobin levels in thalassemia major, inevitably lead to iron overload due to the lack of a physiological mechanism for excess iron excretion. Iron overload can manifest as fatigue, skin hyperpigmentation and hepatomegaly.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Insufficient blood transfusions:</span></strong><span style=\"font-size:12.0pt\"> The patient is adhering to the transfusion schedule, and his hemoglobin level is within the target range for thalassemia major. Thus, insufficient transfusions are unlikely to be the cause of his symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Folate deficiency:</span></strong><span style=\"font-size:12.0pt\"> Folate deficiency typically causes megaloblastic anemia with macrocytic red blood cells. This is not consistent with the patient&#39;s history of thalassemia major or the presentation with microcytic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vitamin B12 deficiency:</span></strong><span style=\"font-size:12.0pt\"> Similar to folate deficiency, vitamin B12 deficiency causes megaloblastic anemia, which is inconsistent with the patient&#39;s presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron chelation therapy is crucial in patients with thalassemia major receiving regular transfusions to prevent iron overload and its associated complications.</span></span></span></p>",
      "correct_choice_id": 82736,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20695,
      "choices": [
        {
          "id": 82743,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Deferoxamine </span></span></span></p>"
        },
        {
          "id": 82744,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Deferiprone </span></span></span></p>"
        },
        {
          "id": 82745,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Deferasirox </span></span></span></p>"
        },
        {
          "id": 82746,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both B and C</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following chelating agents is administered orally for the treatment of iron overload in patients with thalassemia major?</span></span></span></p>",
      "unique_key": "Q4141842",
      "question_audio": null,
      "question_video": null,
      "map_id": 20657,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Both B and C</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both <strong>deferiprone</strong> and <strong>deferasirox</strong> are oral iron chelators used in the management of iron overload in thalassemia major. They are easier to administer than the intravenous chelator, deferoxamine, and can improve patient compliance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A. Deferoxamine:&nbsp;</strong>Deferoxamine&nbsp;is an intravenous iron chelator and requires subcutaneous infusion over several hours, making it less convenient for long-term use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral iron chelators like deferiprone and deferasirox have revolutionized the management of iron overload in thalassemia major by offering a more convenient and less invasive alternative to deferoxamine. Early and consistent chelation therapy is crucial for preventing iron-related complications and improving the quality of life for patients with thalassemia major.</span></span></span></p>",
      "correct_choice_id": 82746,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20696,
      "choices": [
        {
          "id": 82747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive direct antiglobulin test (DAT) with anti-IgG specificity </span></span></span></p>"
        },
        {
          "id": 82748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive DAT with anti-C3d specificity </span></span></span></p>"
        },
        {
          "id": 82749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive DAT with anti-IgM specificity </span></span></span></p>"
        },
        {
          "id": 82750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Negative DAT</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with anemia and acrocyanosis that worsens in cold weather. Which of the following laboratory findings is most consistent with cold agglutinin syndrome (CAS)?</span></span></p>",
      "unique_key": "Q1149006",
      "question_audio": null,
      "question_video": null,
      "map_id": 20658,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Positive DAT with anti-IgM specificity</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CAS is caused by IgM autoantibodies that bind to red blood cells at low temperatures, leading to agglutination and hemolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Positive direct antiglobulin test (DAT) with anti-IgG specificity&nbsp;</span></strong><span style=\"font-size:12.0pt\">and <strong>Option</strong> <strong>B. Positive DAT with anti-C3d specificity</strong> are more commonly associated with WAIHA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Negative DAT</strong>:</span><strong><span style=\"font-size:12.0pt\">&nbsp;</span></strong><span style=\"font-size:12.0pt\">A negative DAT would not be expected in a patient with autoimmune hemolytic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A positive DAT with anti-IgM specificity is a key laboratory finding in the diagnosis of CAS.</span></span></span></p>",
      "correct_choice_id": 82749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20698,
      "choices": [
        {
          "id": 82755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cold agglutinin disease (CAD) </span></span></span></p>"
        },
        {
          "id": 82756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paroxysmal cold hemoglobinuria (PCH) </span></span></span></p>"
        },
        {
          "id": 82757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Warm autoimmune hemolytic anemia (WAIHA) </span></span></span></p>"
        },
        {
          "id": 82758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microangiopathic hemolytic anemia (MAHA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with a history of lymphoma presents with fatigue, jaundice, and splenomegaly. Peripheral blood smear shows spherocytes. Which of the following is the MOST likely diagnosis?</span></span></p>",
      "unique_key": "Q7585563",
      "question_audio": null,
      "question_video": null,
      "map_id": 20660,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Warm autoimmune hemolytic anemia (WAIHA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of fatigue, jaundice, and splenomegaly, along with spherocytes on peripheral smear, is most consistent with WAIHA. The history of lymphoma increases the likelihood of WAIHA, as some types of lymphoma can trigger autoimmune responses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cold agglutinin disease (CAD):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Primarily presents with acrocyanosis and anemia, and blood smear often reveals agglutination.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Paroxysmal cold hemoglobinuria (PCH):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Paroxysmal cold hemoglobinuria (PCH)&nbsp;is rare and typically presents with biphasic hemolysis and hemoglobinuria after cold exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Microangiopathic hemolytic anemia (MAHA):</span></strong><span style=\"font-size:12.0pt\"> Presents with schistocytes on peripheral smear and is associated with underlying conditions like thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WAIHA is the most common type of autoimmune hemolytic anemia and can be associated with underlying lymphoproliferative disorders like lymphoma</span></span></span></p>",
      "correct_choice_id": 82757,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}